Last reviewed · How we verify
Dexmedetomidine C
Dexmedetomidine C is a Small molecule drug developed by Guangzhou General Hospital of Guangzhou Military Command. It is currently FDA-approved. Also known as: Dexmedetomidine in elderly female group.
At a glance
| Generic name | Dexmedetomidine C |
|---|---|
| Also known as | Dexmedetomidine in elderly female group |
| Sponsor | Guangzhou General Hospital of Guangzhou Military Command |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of C-Reactive Protein Levels in Traumatic Brain Injury Patients Undergoing Craniotomy With and Without Dexmedetomidine (PHASE4)
- Electrophysiologist-led Deep Sedation Protocols for Pulsed Field Ablation for Atrial Fibrillation Using a Bipolar Tip-Catheter: The DEEP-PFA Randomized Controlled Trial (NA)
- Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department (PHASE4)
- Dexmedetomidine vs Ketamine as Adjuvants to Bupivacaine in Transversus Abdominus Plane Block in Inguinal Hernioplasty (PHASE3)
- Oral Melatonin Versus Nebulized Dexmedetomidine on Emergence Agitation in Children Undergoing Adenotonsillectomy (NA)
- Effect of Total Intravenous Anesthesia vs Inhalational Anesthesia on the Level of Inflammatory Markers (NA)
- Perineural Dexamethasone, Dexmedetomidine, or Their Combination to Reduces Rebound Pain After Supraclavicular Brachial Plexus Block (PHASE4)
- The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavioral Changes in Children With Autism Spectrum Disorder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine C CI brief — competitive landscape report
- Dexmedetomidine C updates RSS · CI watch RSS
- Guangzhou General Hospital of Guangzhou Military Command portfolio CI
Frequently asked questions about Dexmedetomidine C
What is Dexmedetomidine C?
Dexmedetomidine C is a Small molecule drug developed by Guangzhou General Hospital of Guangzhou Military Command.
Who makes Dexmedetomidine C?
Dexmedetomidine C is developed and marketed by Guangzhou General Hospital of Guangzhou Military Command (see full Guangzhou General Hospital of Guangzhou Military Command pipeline at /company/guangzhou-general-hospital-of-guangzhou-military-command).
Is Dexmedetomidine C also known as anything else?
Dexmedetomidine C is also known as Dexmedetomidine in elderly female group.
What development phase is Dexmedetomidine C in?
Dexmedetomidine C is FDA-approved (marketed).
Related
- Manufacturer: Guangzhou General Hospital of Guangzhou Military Command — full pipeline
- Also known as: Dexmedetomidine in elderly female group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing